Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPublications section updated to indicate that PubMed publications are automatically filled and may not be about the study. The page revision now shows 'Revision: v3.3.2' and the previous wording with 'Revision: v3.2.0' was removed.SummaryDifference0.1%

- Check18 days agoChange DetectedThe government funding/operating status notice was removed from the page; this is a non-significant change that does not affect study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check40 days agoChange DetectedThe changes appear to be cosmetic: the page's layout/formatting has been updated, but there is no visible modification to core study details such as title, objectives, design, outcomes, eligibility criteria, enrollment, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check62 days agoChange Detected- Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.SummaryDifference4%

- Check69 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check83 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' navigation item has been removed. No substantive content changes were detected.SummaryDifference0.2%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.